RxDoctor Payments Data

Diana Sutherland, NP

Gerontology · Cincinnati, OHNPI 1346633765

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 90.5% of it on its own, with 15 other manufacturers making up the rest. Among gerontology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,948in general payments, 2019–2025

Across 107 payments — averaging $298.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$29K
  • Novartis$1K
  • Daiichi Sankyo Inc.$395
  • Seagen Inc.$317
  • Astellas Pharma US Inc$140
  • Pfizer$134
  • plus $668 from 10 others

What the payments were for

  • Consulting fees$2,8889%
  • Speaking & faculty fees$18,50058%
  • Travel & lodging$6,38120%
  • Food & beverage$3,77012%
  • Education$4101%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,948 in reported general payments places this provider in the 95th percentile of 361 gerontology providers in Ohio.

See all gerontology providers in Ohio

Medicare billing

Part B allowed, 2024
$16,182
Medicare patients
144
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib34$515,930
VerzenioAbemaciclib21$289,216
KisqaliRibociclib Succinate11$166,686
EliquisApixaban30$24,096
XareltoRivaroxaban11$10,452
Exemestane91$10,134
Letrozole325$6,142
Lidocaine12$1,224
Anastrozole77$1,102
Oxycodone Hcl49$982
Tamoxifen Citrate30$622
Gabapentin36$509
Potassium Chloride26$444
Venlafaxine Hcl ErVenlafaxine Hcl25$402
Alendronate Sodium66$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$134$540,02664 claims
Lilly USA, LLCVerzenio$15$289,21621 claims
NovartisKisqali$1,392$166,68611 claims
Johnson & JohnsonXarelto$97$10,45211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 gerontology providers in Ohio.

Other gerontology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →